Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective，Multicenter，Randomized Trial of Biweekly Single-dose Actinomycin-D Versus Multi-day Methotrexate Protocol for the Treatment of Low-risk Gestational Trophoblastic Neoplasia

NCT04562558 is registered in ClinicalTrials.gov with xiang yang as lead sponsor.

NCT NCT04562558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04562558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective，Multicenter，Randomized Trial of Biweekly Single-dose Actinomycin-D Versus Multi-day Methotrexate Protocol for the Treatment of Low-risk Gestational Trophoblastic Neoplasia
Lead sponsor
xiang yang
Phase
Not applicable
Overall status
Active, not recruiting
Start date
September 29, 2020
Completion date
December 31, 2025
Enrollment
228 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

choriocarcinoma, gestational trophoblastic neoplasia, gestational trophoblastic tumor, invasive mole, stage i gestational trophoblastic tumor, stage ii gestational trophoblastic tumor, stage iii gestational trophoblastic tumor